#AUA14 - Poster: Further characterization of the effects of prior or no prior docetaxel therapy on CRPC patients with bone metastases receiving Ra-223 in the phase 3 ALSYMPCA trial

ORLANDO, FL USA (UroToday.com) - Presented by Neal D. Shore,1 Nicholas J. Vogelzang,2 Peter Hoskin,3 Sten Nilsson,4 Robert Coleman,5 Christopher Parker,6 Mona Wahba,7 Karin Staudacher,8 and Oliver Sartor9 at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

aua 2014 ra223 shore poster thumb

1Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA; 2Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA; 3Mount Vernon Hospital Cancer Centre, Northwood, UK; 4Karolinska University Hospital, Stockholm, Sweden; 5Weston Park Hospital, Sheffield, UK; 6The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK; 7Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA; 8Algeta ASA (Bayer), Oslo, Norway; 9Tulane Cancer Center, New Orleans, LA, USA

Click HERE to read an exclusive report by a UroToday medical writer

 

 

 

email news signup